{"id":"gm-csf-priming","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Leukocytosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GM-CSF (granulocyte-macrophage colony-stimulating factor) is a cytokine that promotes the differentiation, proliferation, and activation of myeloid cells including neutrophils, macrophages, and dendritic cells. Priming with GM-CSF before other immunotherapies or treatments aims to enhance the immunogenicity of the tumor microenvironment and improve the efficacy of subsequent immune-mediated anti-tumor responses.","oneSentence":"GM-CSF priming enhances immune cell activation and recruitment by stimulating granulocyte-macrophage colony-stimulating factor signaling to prime myeloid cells for improved anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:11.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer immunotherapy priming (phase 3 investigational)"}]},"trialDetails":[{"nctId":"NCT06254326","phase":"PHASE1","title":"ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2024-09-19","conditions":"Recurrent Oligodendroglioma, Progressive Oligodendroglioma","enrollment":12},{"nctId":"NCT04978727","phase":"PHASE1","title":"A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-07-01","conditions":"Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":35},{"nctId":"NCT02455557","phase":"PHASE2","title":"SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2015-05-04","conditions":"Glioblastoma, Gliosarcoma","enrollment":66},{"nctId":"NCT03909412","phase":"PHASE1","title":"Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2019-10-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT06514898","phase":"PHASE1","title":"Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-05-05","conditions":"Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma","enrollment":12},{"nctId":"NCT02380443","phase":"PHASE2","title":"AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Mirror Biologics, Inc.","startDate":"2016-09","conditions":"Colorectal Cancer Metastatic","enrollment":13},{"nctId":"NCT04713371","phase":"PHASE2","title":"A Phase 2 Trial for Patients With Metastatic Solid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rampart Health, L.L.C.","startDate":"2021-05-19","conditions":"Metastatic Cancer","enrollment":32},{"nctId":"NCT04300244","phase":"PHASE2","title":"Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Åslaug Helland","startDate":"2020-05-04","conditions":"Cancer, Cancer, Lung, Cancer of Lung","enrollment":118},{"nctId":"NCT00389610","phase":"PHASE2","title":"Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-09-11","conditions":"Pancreatic Cancer","enrollment":56},{"nctId":"NCT04446052","phase":"PHASE3","title":"Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1993-05-21","conditions":"Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia","enrollment":362},{"nctId":"NCT01064375","phase":"PHASE1, PHASE2","title":"Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer","status":"COMPLETED","sponsor":"Maria Liljefors","startDate":"2009-12","conditions":"Colorectal Cancer","enrollment":16},{"nctId":"NCT03003676","phase":"PHASE1","title":"A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade","status":"COMPLETED","sponsor":"Targovax Oy","startDate":"2016-12","conditions":"Advanced or Unresectable Melanoma Progressing After PD1 Blockade","enrollment":21},{"nctId":"NCT02879669","phase":"PHASE1, PHASE2","title":"A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma","status":"UNKNOWN","sponsor":"Targovax Oy","startDate":"2016-06","conditions":"To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy","enrollment":31},{"nctId":"NCT00002950","phase":"PHASE1, PHASE2","title":"Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"1996-09-26","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":25},{"nctId":"NCT01245673","phase":"PHASE2","title":"Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-05-10","conditions":"Myeloma","enrollment":28},{"nctId":"NCT00834665","phase":"PHASE1","title":"Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2006-12","conditions":"Multiple Myeloma","enrollment":59},{"nctId":"NCT00847171","phase":"PHASE2","title":"Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-12","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT00005987","phase":"PHASE2","title":"Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2000-08","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":87},{"nctId":"NCT00791037","phase":"PHASE1, PHASE2","title":"Vaccine Therapy in Treating Patients With Stage IV Breast Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2008-10","conditions":"HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer","enrollment":23},{"nctId":"NCT00669136","phase":"PHASE1","title":"Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Lisa H. Butterfield, Ph.D.","startDate":"2009-06","conditions":"Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult","enrollment":2},{"nctId":"NCT00499577","phase":"PHASE1, PHASE2","title":"Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"University of Maryland Greenebaum Cancer Center","startDate":"2006-12","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":56},{"nctId":"NCT00004036","phase":"PHASE1","title":"Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer","status":"UNKNOWN","sponsor":"The Cleveland Clinic","startDate":"1997-11","conditions":"Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia","enrollment":30},{"nctId":"NCT00016042","phase":"PHASE1","title":"Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer","status":"UNKNOWN","sponsor":"St. Luke's Medical Center","startDate":"2001-01","conditions":"Colorectal Cancer, Kidney Cancer","enrollment":""},{"nctId":"NCT00030342","phase":"PHASE1, PHASE2","title":"Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer","status":"COMPLETED","sponsor":"St. Luke's Medical Center","startDate":"2001-11","conditions":"Colorectal Cancer, Kidney Cancer","enrollment":60},{"nctId":"NCT00085423","phase":"PHASE2","title":"Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2004-02","conditions":"Melanoma (Skin)","enrollment":20},{"nctId":"NCT00323557","phase":"PHASE2","title":"Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-06","conditions":"Leukemia","enrollment":39},{"nctId":"NCT00093548","phase":"PHASE1, PHASE2","title":"Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"","conditions":"Liver Cancer","enrollment":""},{"nctId":"NCT00616564","phase":"PHASE2","title":"Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma","status":"COMPLETED","sponsor":"Mt. Sinai Medical Center, Miami","startDate":"2006-02","conditions":"Malignant Melanoma","enrollment":36},{"nctId":"NCT00880243","phase":"PHASE3","title":"Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Acute Leukemia French Association","startDate":"1999-03","conditions":"Acute Myeloid Leukemia","enrollment":473},{"nctId":"NCT00140387","phase":"PHASE1, PHASE2","title":"Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)","status":"COMPLETED","sponsor":"Cell Genesys","startDate":"1999-05","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT00140400","phase":"PHASE1, PHASE2","title":"Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Cell Genesys","startDate":"1999-05","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT00140374","phase":"PHASE1, PHASE2","title":"Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)","status":"COMPLETED","sponsor":"Cell Genesys","startDate":"1998-12","conditions":"Prostate Cancer","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":54,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GM-CSF priming","genericName":"GM-CSF priming","companyName":"Eastern Cooperative Oncology Group","companyId":"eastern-cooperative-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GM-CSF priming enhances immune cell activation and recruitment by stimulating granulocyte-macrophage colony-stimulating factor signaling to prime myeloid cells for improved anti-tumor immunity. Used for Cancer immunotherapy priming (phase 3 investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}